18
In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.
 patients: Subject; secondary effects of antitumor agents on other drugs: Effect; 5-FU increased PHT, which in turn may have increased the PB concentration: Treatment; 5-FU: Treatment.Drug; PHT: Treatment.Drug; 5-FU: Combination.Drug; PHT: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients: Subject; secondary effects of antitumor agents on other drugs: Effect; 5-FU increased PHT, which in turn may have increased the PB concentration: Treatment; 5-FU: Treatment.Drug; PHT: Treatment.Drug; 5-FU: Combination.Drug; PHT: Combination.Drug